Dipti Talaulikar
Expertise in
8
conditions

Dipti Talaulikar

Canberra, ACT, AU 
Expertise in
8
conditions
Canberra, ACT, AU 

Overview

Dipti Talaulikar practices practicing medicine in Canberra, Australia.

Ms. Talaulikar is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Waldenstrom Macroglobulinemia, Diffuse Large B-Cell Lymphoma (DLBCL), Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), Bone Marrow Transplant, and Tissue Biopsy.

She is actively involved in clinical research, co-authoring 102 peer reviewed articles and participating in 1 clinical trial.

Gender

Female

Locations

Canberra, ACT, Australia
Other Locations
Australian Capital Territory, Australia
Sydney, NSW, Australia
Garran, ACT, Australia
Acton, ACT, Australia
Melbourne, VIC, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: BGB-3111 (Zanubrutinib), Ibrutinib
Study Phase: Phase 3

102 Total Publications

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.
Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026

Frequently Asked Questions about Dipti Talaulikar

Is Dipti Talaulikar a top-rated expert for Waldenstrom Macroglobulinemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dipti Talaulikar is classified as an Distinguished expert for Waldenstrom Macroglobulinemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Dipti Talaulikar participate in research or clinical trials?

Yes. Dipti Talaulikar has published 102 articles and abstracts on conditions like Waldenstrom Macroglobulinemia. You can view a list of Dipti Talaulikar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Talaulikar's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile